Treatment

test

Velcade shown effective against Mantle Cell Lymphoma

Well, it was nearly 2 years ago when I first wrote about new trials of Velcade® (bortezomib) for treating Mantle Cell Lymphoma, a stubborn form of NHL that has resisted treatment for many patients.

Zolinza (Vorinostat or SAHA) Trials

A couple blogs ago, I posted about the use of Vorinostat (also known as SAHA, brand name Zolinza) for use in Cutaneous T-Cell Lymphoma.

When I was posting some new personal blogs on Hodgkin's Lymphoma, and I saw one person was in a clinical trial for SAHA! Sure enough, if you do a search of Hodgkin's trials on clinicaltrials.gov, there are two trials accepting Hodgkin's patients. Overall there appear to be six trialsfor the drug for different lymphomas.

Teen who went to court on Hodgkin's treatment doing ok

Three months after settling a highly publicized fight with Virginia officials over whether he could refuse conventional medical treatment, Starchild Abraham Cherrix appears to be making major progress.

"I feel amazing. I'm just a ball of fire now," Cherrix said en route to their home on Virginia's Eastern Shore. They had spent the past six weeks in Mississippi, where Cherrix was treated by a new oncologist for Hodgkin's disease.

Cutaneous T-cell lymphoma: US FDA approval of Zolinza

The United States Food and Drug Administration has approved Zolinza (generic name Vorinostat, also known as SuberoylAnilide Hydroxamic Acid or SAHA) ) capsules for the treatment of advanced cutaneous T-cell lymphoma (CTCL), a lymphoma of the skin.

Zolinza is the first in a new class of anti-cancer therapies called histone deacetylase (HDAC ) inhibitors.

New Phase III Clinical Trial with Anticancer Drug Zevalin

Schering AG and Biogen Idec announced October 4th the start of the ZEAL study (ZEVALIN as consolidation therapy in Aggressive Lymphoma). Approximately 400 patients with Non-Hodgkin’s Lymphoma (NHL) will be enrolled in this Phase III, international multi-center clinical trial.

Antibiotic Treats Lymphoma Near the Eye

The common antibiotic doxycycline effectively treats a type of lymphoma associated with chlamydia infection, according to a study in the October 4 issue of the Journal of the National Cancer Institute.

Ocular adnexal lymphoma of the MALT-type (OAL) is a kind of cancer of the eyelids and related tissues. It is not often fatal, but its symptoms can compromise a patient's quality of life. Some research has suggested an association between OAL and infection with the bacteria Chlamydia psittaci.

CHOP + Zevalin and Rituxan better than CHOP + Rituxan Alone

Results from a phase II clinical trial reported that CHOP-R followed by Zevalin (90Y ibritumomab tiuxetan) and Rituxan (rituximab, MabThera outside the US) provides high complete response rates and encouraging progression-free survival as initial treatment of follicular non-Hodgkin’s lymphoma (NHL). These results were presented at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO).

More info in a press release.

The Making of a Monoclonal Antibody

In cancer treatment today, three letters have infiltrated the oncology dialect: "mab," as in rituximab (Rituxan), tositumomab (Bexxar), or Ibritumomab tiuxetan (Zevalin). This suffix is reserved formonoclonal antibodies - agents that have become a growing component of the oncologist's arsenal.

Currently, eight monoclonal antibodies, or MAbs, are approved by the FDA to treat cancer. And many more are being tested in phase II and III clinical trials for a variety of tumor types.

Millennium Files sNDA for Velcade for Mantle Cell NHL

Millennium Pharmaceuticals announced it has filed a supplemental new drug application (sNDA) with the U.S. FDA for Velcade (Bortezomib) in the treatment of relapsed or refractory mantle cell lymphoma (MCL), anaggressive subtype of non-Hodgkin's lymphoma (NHL). The filing is based on final data from the Phase II trial, one of the largest multi-center studies in relapsed MCL to date, which showed a 33 percent overall response rate and an eight percent complete response rate. Importantly, the median duration of response was 9.2 months; 13.5 months in patients achieving a complete response.

Zevalin Used in Auto Stem Cell Transplant Effective for Chemo Resistant Aggressive NHL

Researchers from Israel reported at ASCO this week that the use of Zevalin (Yttrium 90 Ibritumomab Tiuxetan) used with high-dose chemotherapy and autologous stem cell transplant provides an effective treatment option for patients with aggressive non-Hodgkin’s lymphoma (NHL) in first or subsequent relapse.